We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Intellectual Property

  • September 20, 2018

    Tech Co. Tries To DQ Ex-Exec's Attys Over Privileged Docs

    A data security startup on Wednesday moved to disqualify the lawyers representing its ousted co-founder in a suit in California federal court accusing him of sharing trade secrets with technology giant Oracle Corp., saying the co-founder's attorneys had weaponized privileged documents he allegedly stole.

  • September 20, 2018

    ITC Clears Vizio, Sigma In Broadcom Chip Patent Suit

    The U.S. International Trade Commission has found that Broadcom failed to show that TV maker Vizio and semiconductor maker Sigma Designs sold and imported products that infringed two patents on video coding and graphics technology, closing the book on a case that sought to bar imports of the companies’ products.

  • September 20, 2018

    Morgan Stanley Says Ex-Brokers Tried To Woo Clients To Stifel

    Morgan Stanley alleged Wednesday in Illinois federal court that six financial advisers who previously managed $660 million for the bank attempted to take confidential information and clients when they left for competitor Stifel Nicolaus & Co.

  • September 20, 2018

    Groupon Says $82M Verdict In IBM Patent Suit Was Too High

    Groupon Inc. asked a Delaware federal court on Wednesday to toss what it claims was a "runaway jury verdict" awarding $82.5 million to IBM Corp. after finding Groupon infringed four e-commerce patents dating back to the early days of personal computing.

  • September 19, 2018

    UnitedHealthcare Can't Take Back Cephalon Antitrust Deal

    A Pennsylvania federal judge has found that UnitedHealthcare Services Inc. is bound by a $125 million antitrust settlement its outside counsel reached with Cephalon Inc., as the insurer had given every indication that its lawyers were in the clear to sign on its behalf and in-house counsel actively chose not to read or challenge the final agreement.

  • September 19, 2018

    PTAB Denial Of Nike Shoe Patent Amendment Prompts Debate

    The Patent Trial and Appeal Board has once again refused to allow Nike Inc. to amend a footwear patent that was challenged by rival Adidas AG, in a decision Tuesday that prompted a debate among judges about the standard for determining what is a reasonable number of substitute claims.

  • September 19, 2018

    Qualcomm Can't Fast-Track Bid To Ax Apple's Patent Claims

    Qualcomm has failed to convince a California federal judge to hasten proceedings on its effort to dust aside certain patent-related claims by Apple in the pair’s ongoing legal brawl, with the judge agreeing on Wednesday with Apple’s argument that “extreme expedited treatment” was not warranted.

  • September 19, 2018

    Pfizer Unit, Teva Must Face Effexor Antitrust Litigation

    Pfizer Inc. unit Wyeth and Teva Pharmaceuticals have fallen short in their bid to ax a proposed class action from end-payors alleging the companies engaged in a scheme to delay generic competition for antidepressant drug Effexor XR, with a New Jersey federal judge refusing to toss the case in its entirety.

  • September 19, 2018

    Amazon Accused Of Infringing Patented 'Twisty' Pipe

    The maker of a corkscrew pipe popularly used to smoke marijuana has accused Amazon in Massachusetts federal court of infringing a patent on the glass blunt known as Twisty by enabling third-party merchants to sell knockoff versions on the world's most popular retail website.

  • September 19, 2018

    First Amendment Protects 'Patent Troll' Moniker, ACLU Says

    Calling a company a "patent troll" isn't defamatory, the American Civil Liberties Union and the Electronic Frontier Foundation have argued in an amicus brief filed with the New Hampshire Supreme Court, saying it's a form of rhetorical hyperbole.

  • September 19, 2018

    No Need To Reconsider Immunity At PTAB, Fed. Circ. Hears

    Mylan Pharmaceuticals Inc. and other generic-drug companies challenging Allergan PLC patents for dry-eye medication Restasis urged the full Federal Circuit on Tuesday not to reconsider an earlier decision that tribal sovereign immunity doesn’t apply in reviews at the Patent Trial and Appeal Board.

  • September 19, 2018

    Fed. Circ. Affirms Validity Of Cybersecurity Patent

    The Federal Circuit on Wednesday affirmed a Patent Trial and Appeal Board decision that a malware detection patent asserted against Palo Alto Networks Inc. is not obvious.

  • September 19, 2018

    HP Gets Statements Tied To Fraud Claims Booted Mid-Trial

    A California judge Wednesday struck a mid-trial blow to a startup alleging Hewlett Packard coerced it into providing tens of millions of dollars of extra software and services on a Malaysian project, ruling that an HP employee’s statements related to the case’s fraud claims aren’t admissible.

  • September 19, 2018

    Allergan Loses 'Meritless' Bid To Gut Restasis Antitrust MDL

    A New York federal judge has shot down Allergan Inc.’s “meritless” effort to eviscerate multidistrict litigation that alleges antitrust violations aimed at protecting dry-eye drug Restasis, saying it’s plausible that the company acted dishonestly to stymie generic competition.

  • September 19, 2018

    Ding Dong Ditch: Orrick DQ'd In Video Doorbell IP Dispute

    A California federal court has disqualified Orrick Herrington & Sutcliffe LLP from representing a video doorbell company in a patent suit brought by a rival, ruling the firm received confidential information from the rival before the suit was filed.

  • September 19, 2018

    'Shake It Off' Case Against Taylor Swift Heads To 9th Circ.

    Two songwriters who unsuccessfully sued Taylor Swift for copyright infringement over “Shake It Off” are taking their case to the Ninth Circuit, at one point quoting a judge who told the pop star to “be careful what you wish for.”

  • September 19, 2018

    CloudFlare Wants Fees, Says 'Bad Faith' IP Suit Dragged On

    CloudFlare Inc. on Wednesday said it is entitled to $200,000 in attorneys' fees for defending against bad faith litigation full of "red flags," telling a California federal judge that the tech startup Swarmify Inc. kept pursuing its trade secrets claims even after it knew in February that it didn't have a case.

  • September 19, 2018

    Texas Standing-Desk Maker Reaches Deals In Patent Probe

    A desk maker in Texas on Tuesday said it has reached deals with several companies to end a U.S. International Trade Commission probe into its complaint that the companies, which are located in the U.S. and China, infringed patents for its standing desk platforms.

  • September 18, 2018

    Senate Passes Streaming Music Royalties Overhaul

    The U.S. Senate on Tuesday voted unanimously in favor of legislation that would make major changes to how streaming music services like Spotify pay royalties.

  • September 18, 2018

    Northrop Blocks NASA From Releasing Contract In FOIA Filing

    A D.C. federal judge on Tuesday sided with Northrop Grumman Systems Corp. in its bid to block NASA from fulfilling a Freedom of Information Act request that the defense contractor had claimed would have exposed details about a subsidiary's contract and pricing practices.

Expert Analysis

  • In Calif., Questions Remain On Law Firm Conflict Waivers

    Richard Rosensweig

    In Sheppard Mullin v. J-M Manufacturing Co., the California Supreme Court ruled last month that a law firm's failure to disclose a known conflict with another current client did not categorically disentitle the firm from recovering fees. But the court didn’t provide hoped-for guidance on how to write an enforceable advance conflict waiver, says Richard Rosensweig of Goulston & Storrs PC.

  • Q&A

    A Chat With Faegre Client Development Chief Melanie Green

    Melanie Green

    In this monthly series, Amanda Brady of Major Lindsey & Africa interviews management from top law firms about the increasingly competitive business environment. Here we feature Melanie Green, chief client development officer at Faegre Baker Daniels LLP.

  • Design Patent Confusion In Fed. Circ. Maatita Ruling

    Robert Anders

    The Federal Circuit's decision last month in Maatita effectively eliminates the design patent requirement that drawings must enable a person of skill in the art to make and use the invention. The court failed to properly apply statutory standards, leading to an improper result, say Robert Anders of A Design Consultancy and Christopher Rourk of Jackson Walker LLP.

  • Unpacking The New Temporary Rules For Bonus Depreciation

    Ellen McElroy

    Last year’s business-friendly amendment of Internal Revenue Code Section 168(k), which allows immediate expensing for certain business assets, left many questions. In August, the Department of Treasury proposed rules clarifying requirements for depreciable property, but not all solutions are permanent and many issues remain unresolved, say attorneys at Eversheds Sutherland LLP.

  • Intellectual Property Caught In US-China Trade Crossfire

    Holly White

    Earlier this year, President Donald Trump imposed tariffs on Chinese products as a response to China’s trade practices concerning technology transfer, intellectual property and innovation. The U.S.-Chinese trade war highlights the need to approach investments in China differently, taking a broad view of intellectual assets and looking beyond basic legal protection, says Holly White, a consultant at Rouse & Co.

  • Opinion

    Court Doubles Down On Incorrect Right Of Publicity Ruling

    Ronald Katz

    A California federal court's refusal last week to reconsider Davis v. Electronic Arts magnifies the manifest errors in its recent decision by ignoring the blatantly obvious identifiability of the former NFL players, says Ronald Katz of GCA Law Partners LLP.

  • When Courts Allow Changes To Hatch-Waxman 30-Month Stay

    Jeffrey Lewis

    Decisions granting extensions of 30-month stays under the Hatch-Waxman Act are infrequent and often not reported. This small body of cases provides helpful benchmarks for parties, say Jeffrey Lewis and Niki Ikahihifo-Bender of Norton Rose Fulbright.

  • Amgen Suit Shows Limitations Of Biosimilar Safe Harbor

    Julia Kolibachuk

    A Delaware federal court's ruling in Amgen v. Hospira last month may indicate a significant narrowing of the patent infringement exception for activities related to obtaining drug approval from the U.S. Food and Drug Administration, say attorneys at Paul Hastings LLP.

  • Fed. Circ. Redefines 'Real Party In Interest' In USPTO Reviews

    Craig Countryman

    The Federal Circuit’s decision in Applications in Internet Time v. RPX expansively interprets the term “real party in interest” and creates new hurdles for companies that ask the U.S. Patent and Trademark Office to institute an inter partes or post-grant review, says Craig Countryman of Fish & Richardson PC.

  • Early Strategies For Protecting Neural Network Inventions

    Frank DeCosta

    Companies are heavily investing in artificial neural networks and implementing them into products and businesses. This technology provides a vivid illustration of some of the challenges in seeking intellectual property protection for artificial intelligence, say attorneys with Finnegan Henderson Farabow Garrett & Dunner LLP.